Literature DB >> 16042978

Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs.

Gabriella Gobbi1, Pierre Blier.   

Abstract

Neurokinin-1 (NK1) receptor antagonists have been reported to possess antidepressant and anxiolytic properties in controlled trials. Since antidepressant and anxiolytic drugs act mainly by enhancing serotonin (5-HT) and norepinephrine (NE) neurotransmission in forebrain areas, the main focus of the present review is to critically examine the electrophysiological effects of NK1 receptor antagonists on serotoninergic and noradrenergic neurons, and then hippocampal neurons. It is concluded that NK1 antagonists increase the firing and burst activity of 5-HT neurons, increase burst activity of NE neurons, and modulate postsynaptic transmission at the hippocampus level. Further research is needed in order to develop more selective ligands for the human NK1 receptor and to gain better knowledge of required brain penetration and optimal pharmacodynamic conditions for their use in patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042978     DOI: 10.1016/j.peptides.2005.03.032

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  13 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

2.  Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis.

Authors:  G Gobbi; F R Bambico; R Mangieri; M Bortolato; P Campolongo; M Solinas; T Cassano; M G Morgese; G Debonnel; A Duranti; A Tontini; G Tarzia; M Mor; V Trezza; S R Goldberg; V Cuomo; D Piomelli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-13       Impact factor: 11.205

3.  Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.

Authors:  Antonio Inserra; Justine P Enns; Danilo De Gregorio; Athanasios Markopoulos; Michael Pileggi; Youssef El Rahimy; Martha Lopez-Canul; Stefano Comai; Gabriella Gobbi
Journal:  Neuropsychopharmacology       Date:  2022-03-17       Impact factor: 8.294

4.  Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release.

Authors:  Karl Ebner; Nicolas Singewald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-19       Impact factor: 3.000

Review 5.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

Review 6.  Beneficial effects of moderate voluntary physical exercise and its biological mechanisms on brain health.

Authors:  Qiang Ma
Journal:  Neurosci Bull       Date:  2008-08       Impact factor: 5.203

7.  Utilization of the least shrew as a rapid and selective screening model for the antiemetic potential and brain penetration of substance P and NK1 receptor antagonists.

Authors:  Nissar A Darmani; Yaozhi Wang; Joseph Abad; Andrew P Ray; Gerald R Thrush; Juan Ramirez
Journal:  Brain Res       Date:  2008-04-09       Impact factor: 3.252

8.  Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.

Authors:  Tiffany W Chow; Bruce G Pollock; Norton W Milgram
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

9.  Anxiolytic and Antidepressant-Like Effects of the Aqueous Extract of Alafia multiflora Stem Barks in Rodents.

Authors:  Harquin Simplice Foyet; David Emery Tsala; Armand Abdou Bouba; Lucian Hritcu
Journal:  Adv Pharmacol Sci       Date:  2012-10-22

10.  Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.

Authors:  Hitoshi Sakurai; Kengo Yonezawa; Hideaki Tani; Masaru Mimura; Michael Bauer; Hiroyuki Uchida
Journal:  Pharmacopsychiatry       Date:  2022-01-19       Impact factor: 2.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.